milatuzumab
IMMU-115-04
Phase 1 small_molecule completed
Quick answer
milatuzumab for Lupus Erythematosus, Cutaneous is a Phase 1 program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Lupus Erythematosus, Cutaneous
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed